Articles tagged with Drug Targets
Research found that states legalizing recreational cannabis saw a slight increase in alcohol consumption, particularly among young adults and men. The study suggests that targeted public health messaging and policy interventions can mitigate problem drinking. However, the impact of long-term effects on binge or heavy drinking is unclear.
Researchers at University of Pittsburgh have designed novel nanoparticles that co-deliver a chemotherapy drug and a novel immunotherapy, shrinking tumors in mouse models of colon and pancreatic cancer. The therapy silences a gene involved in immunosuppression by blocking Xkr8 protein distribution on the cell membrane.
Researchers identified four partially hidden binding pockets on the SARS-CoV-2 virus's Nsp1 protein that could be targeted with drugs. These pockets are found to halt virus replication and prevent immune system shut-down, providing a promising lead for future coronavirus treatments.
Researchers at Weill Cornell Medicine found a new way to target mantle cell lymphoma by inhibiting the activity of FOXO1 protein, which coordinates gene expression. The discovery could lead to new treatments and improved understanding of how this type of lymphoma develops.
Researchers from Indiana University School of Medicine identified the protein bassoon as a key contributor to tau neurotoxicity in Alzheimer's disease. The study found that bassoon stabilizes the tau seed, allowing it to propagate in the brain and exacerbate neurodegeneration.
A research team developed a vaccine targeting synthetic opioid fentanyl to block its entry into the brain, preventing fatal effects. The breakthrough could have major implications for treating Opioid Use Disorder, with potential relapse prevention capabilities.
Researchers discovered that the Memo1 protein binds copper ions, blocking toxic redox reactions that damage or kill cancer cells. The protein's interaction with copper also protects against metastasis formation in breast cancer cells. This finding opens up potential new treatments for cancer.
Researchers identified Spns2, an S1P transporter, as a novel drug target for Multiple Sclerosis treatment. Targeting this protein may improve safety profiles and reduce side effects associated with current therapies.
Researchers found that MK256 induced differentiation and maturation in leukemia stem cells, inhibiting proliferation of AML cell lines. The study also showed dose-dependent inhibition of the STAT pathway in both in vitro and in vivo studies.
A new study has shown that SGLT-2 inhibitors, a type of diabetes medication, can decrease cardiovascular risk in adults with chronic kidney disease. The meta-analysis included results from 13 major clinical trials and found a 28% lower risk of worsening kidney disease and death from cardiovascular disease.
A new medication, pemafibrate, lowered triglyceride levels among adults with Type 2 diabetes, but did not decrease their cardiovascular risk. The study found that lowering triglyceride levels may not protect against cardiovascular disease in people with Type 2 diabetes.
A new study published in Alzheimer's & Dementia found that telmisartan, a blood pressure medication, is associated with lower risk of Alzheimer's specifically in Black patients over 60. The study analyzed data from over 5 million patients and suggests that future clinical trials should prioritize minority populations to find or reinfor...
Researchers found that rapamycin treatment during developmental growth phase decelerates aging rate and extends lifespan in animals. A transient late-life treatment is not effective, but a transient early-life treatment can reprogram aging.
Researchers at the University of Cincinnati are awarded a $3.5 million NIH grant to examine how alcohol use alone or in combination with fentanyl affects HIV medications, including PrEP medication. The study aims to determine metabolite signatures and pharmacological biomarkers of PrEP in HIV-negative populations.
A recent analysis of COVID-19-positive donor heart transplants found no significant differences in transplant outcomes compared to those from non-COVID-19 donors. The study's results suggest that COVID-19-positive hearts may be as safe for transplantation, potentially addressing the shortage of available donor organs.
The THERACAT project aims to deliver drugs only to tumor sites using bio-orthogonal catalysis, a promising approach for targeted cancer treatment. Researchers developed nanoparticles bearing metal catalysts to efficiently convert inactive pro-drugs into active drugs at the tumor site.
Researchers found that sapanisertib can kill the malaria parasite at several stages during its life cycle, including in the liver and red blood cells. The study's findings offer new hope against a disease that kills over half a million people annually.
A new study found that Black veterans hospitalized with COVID-19 were less likely to receive evidence-based treatments such as steroids and remdesivir compared to their white counterparts. However, the study also found that disparities in treatment did not translate to higher mortality rates or readmission rates among Black patients.
Researchers at VCU Massey Cancer Center have identified a new therapeutic target for triple-negative breast cancer (TNBC), a more aggressive and deadly form of disease. Using CRISPR/CAS9 screening, scientists pinpointed the UBA1 enzyme as an ideal target, which can be inhibited by the novel drug TAK-243 to effectively kill cancer cells.
Scientists at deCODE genetics have discovered rare, protective loss-of-function variants that point to potential drug targets for NAFLD. The study identified biomarkers of disease and disease progression, which can help develop non-invasive diagnostic tools.
A new study suggests that niclosamide, an anthelmintic drug, shows promise in combating exaggerated inflammation associated with severe COVID-19. The drug's anti-inflammatory effects are attributed to its inhibition of the inflammasome mechanism, a protein complex present in defense cells.
The platform enhances neurosurgical procedures by delivering precise treatment and diagnosis in deep brain tissue. Researchers successfully implanted the catheter in live sheep without damage or infection, paving the way for potential human trials within four years.
Researchers developed a new machine-learning approach to classify macrophages, which are key immune cells involved in pro- or anti-inflammatory responses. This technology could be used as a diagnosis tool or to highlight the role of specific cell types in disease environments.
A study found that nicotine from a single cigarette reduces estrogen production in women's brains, which may explain their greater resistance to quitting smoking. The effect was observed in the thalamus, part of the limbic system involved in behavioral responses.
The FDA's warning letters issued in 2020 and 2021 revealed that the regulator is failing to target leading tobacco companies and products most popular among young people. Over 90% of warnings were sent to small online retailers, while flavoured refillable e-cigarette liquids accounted for over 90% of the products cited.
WayPath Pharma has been awarded a $225,000 Phase I Small Business Technology Transfer (STTR) award to develop new metabolic drugs targeting tumor stem cells and crossing the blood-brain barrier. The funding aims to advance treatment options for glioblastoma, a highly aggressive brain cancer with limited treatment options.
Researchers have discovered a novel antimicrobial compound, evybactin, that selectively targets Mycobacterium tuberculosis, a bacteria that causes tuberculosis. This breakthrough could lead to the development of new treatments for tuberculosis without contributing to antibiotic resistance.
Researchers aim to shift policing focus from law enforcement to building strong communities through situational policing. The approach considers connections within the community and collaboratively builds resources.
A new epigenetics drug, tazemetostat, has been found to stop bladder cancer growth by activating the immune system, not just inhibiting tumors. The drug targets the EZH2 gene and is being tested in clinical trials for late-stage bladder cancer.
Scientists have identified a protein that regulates cancer cell spread and normal tissue cell shedding, potentially leading to new treatments. The research suggests that metastasis is not an abnormal process limited to cancer but a normal process used by healthy cells.
Scientists from NTU Singapore have discovered that telomeres are stacked in columns like a spring, leaving DNA exposed to damage. This finding could improve understanding of how humans age and develop cancer, with potential treatments for diseases caused by dysfunctional telomeres.
Researchers from Xi'an Jiaotong-Liverpool University found that brain stimulation combined with a nose spray containing nanoparticles can improve recovery after ischemic stroke. The treatment increased cognitive and motor functions, and weighed more quickly than those treated with TMS alone.
A potential new treatment for glioblastomas, a deadly form of brain tumor, is being researched using the medication letrozole. Studies have shown that letrozole can be effective in killing tumor cells and reaching target tissue safely.
A team from UNIGE and HUG identified a protein regulation mechanism that reduces melanoma cells' capacity to adapt and resist treatment. They found that targeting this mechanism with an enzyme inhibitor reduces therapeutic resistance in all melanoma cells.
Researchers have identified two NLRP sensors, NLRP1 and CARD8, as key players in Coxsackievirus B3-induced heart inflammation. Targeting CARD8 may prevent CVB3 infections from progressing to heart failure. The study provides new insights into the inflammatory response triggered by this common viral cause of viral myocarditis.
The Regional Transition Navigator program aims to connect youth and young adults aged 14-25 with needed resources, emphasizing those at risk of homelessness, human trafficking or substance use disorders. The program's long-term goal is to teach problem-solving skills and provide support for a healthier transition into adulthood.
The Critical Path Institute (C-Path) has established a public-private partnership with the FDA and NIH to advance treatments for rare neurodegenerative diseases. The partnership will leverage C-Path's expertise in data management, quantitative analytics, and regulatory science to accelerate medical product development.
Researchers at Imperial College London discovered a 'silent' mutation in bacteria that helps them evade antibiotics. The mutation alters the structure of an mRNA intermediate, preventing ribosomes from producing protein, and has arisen independently several times globally.
The research team at the University of Würzburg has reported the first structures of UBA6 in complex with either ATP or FAT10, shedding light on its dual recognition capability. The study also identified UBA6 variants that selectively abolish the activation of either ubiquitin or FAT10.
A new antiparasitic compound has shown 100% efficacy in eliminating T. cruzi, the parasite that causes Chagas disease, in mice and non-human primates. The treatment could provide a safer alternative to current medications with significant side effects and variable efficacy.
A study at Washington State University has identified sulfatase-2 as a critical protein driving damage caused by rheumatoid arthritis. The discovery sheds light on molecular processes behind inflammation in the disease and could lead to improved treatments.
Researchers from Tokyo Metropolitan University have developed a method to directly measure the strength of skeletal muscle myotubes by analyzing wrinkles formed on an elastic substrate when stimulated with electric pulses. This new technique is more sensitive than existing measures and has great potential for accelerating drug discover...
Researchers at Tel Aviv University develop a groundbreaking method to eradicate glioblastoma brain tumors by targeting astrocytes and starving them of energy. The study found that in the absence of these brain cells, tumor cells die and are eliminated, offering a promising basis for developing effective medications.
A newly identified link between chronic pain and lung cancer in mice suggests that old drugs such as clonidine, capsaicin, and fluphenazine may offer new treatments for chronic pain. The study found that blocking the BH4 pathway reduced pain sensitivity and decreased tumor growth in mouse models of KRAS-driven lung cancer.
A new American Heart Association statement highlights the need for specialized care in people who inject drugs, a population with a complex approach to manage potentially deadly heart infections. The standard treatment includes six weeks of intravenous antibiotics, but alternative regimens and oral antibiotics may help complete treatment.
A study by Kumamoto University researchers found that a defective isoform of the SIGIRR gene activates an inflammatory pathway associated with cystic fibrosis. This defect leads to decreased expression and function of anti-inflammatory molecules, resulting in severe inflammation.
A new drug has proven effective in treating rheumatoid arthritis, with results at least as good as the current 'gold standard' treatment. The medication targets a specific messenger molecule involved in inflammation and joint damage, offering a new approach to managing autoimmune disease.
A new map of brain stem circuits controlling eating behavior could lead to better obesity treatments. The atlas, built from recent discoveries in mice and human studies, identifies two food intake-suppressing circuits in the brain stem, one causing nausea and another not.
Researchers at Washington University School of Medicine have discovered a new pathway that could help prevent Alzheimer's dementia. Increasing the clearance of waste products in the brain by ramping up a genetic quirk known as readthrough may be effective for other neurodegenerative diseases, such as Parkinson's disease.
Researchers at Karolinska Institutet have developed a potential curative treatment for neuroblastoma, using DHODH blockers in combination with chemotherapy to cure mice with the disease. The treatment has shown promising results and could improve survival rates for children with neuroblastoma.
Researchers have discovered that reduced TGFBR2 abundance is significantly associated with hepatocellular carcinoma (HCC) in patients with cirrhosis. An AI-based process accurately identified HCC tissue, confirming the biomarker's potential for early detection.
A new study estimates that over 5.5 million U.S. adults used hallucinogens in the past year, with a significant increase in LSD use between 2002 and 2019. The study found that PCP use decreased during this period, while Ecstasy use also declined since 2015.
A new UCLA-led study has identified multiple new risk genes for Alzheimer's disease and progressive supranuclear palsy (PSP) by combining new testing methods. The researchers used high-throughput testing to simultaneously test 5,706 genetic variants in 25 loci associated with Alzheimer's and nine loci associated with PSP.
Researchers at Washington University in St. Louis found that cancer cells metabolize glucose in their mitochondria, following conventional biochemical patterns. The study suggests that limiting glucose uptake may not be an effective strategy to target cancer cells, and glucose metabolism may need to be reevaluated as a therapeutic target.
Researchers have developed a new method to efficiently make nano carriers loaded with radioactive salts for both imaging and treatment, offering a promising alternative to chemotherapy. The radiolabelling method allows clinicians to assess whether patients can benefit from chemotherapeutic treatment with micelles.
A study at Tulane University found that recently formed stroke plaques contain messenger RNA that causes inflammation and degrades a protective cap, leading to rupture. This discovery could lead to new tools to stop strokes from happening and develop new drugs or diagnostics to prevent heart attacks and strokes.
A comprehensive analysis of interstitial lung disease diagnosis and treatment in patients who received an antibody drug conjugate known as T-DXd found that close monitoring and proactive management can reduce the risk of ILD. The study results suggest that patient awareness and ongoing education can aid in early detection.
Researchers found that Merkel cell carcinoma (MCC) Glypican-3 (GPC3) is expressed in nearly 70% of MCC tumors and up to 90% of MCPyV-negative cases. GPC3 expression is associated with worse prognosis, including increased risk of death from MCC. This makes GPC3 a promising target for chimeric antigen receptor T cell therapy.
University of Cincinnati researchers are studying whether targeting an inflammation pathway can improve patient results for soldiers with burn injuries combined with traumatic brain injuries. The research focuses on a specific protein that causes inflammation, which can lead to complications such as anemia and death.
Researchers mapped out the brain network responsible for nicotine's negative consequences, opening the door to interventions that boost aversive effects to help people quit smoking. The discovery suggests that manipulating this network could treat nicotine dependence by inducing an acute aversive effect.